Current treatment options in triple negative breast cancer

Breast Disease

Volumn 32, Issue 1-2, 2010, Pages 99-122

  Rodler, Eve ^a   Korde, Larissa ^a   Gralow, Julie ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; INIPARIB; IRINOTECAN; IXABEPILONE; METHOTREXATE; MICROTUBULE INHIBITOR; MITOMYCIN C; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PROGESTERONE RECEPTOR; SORAFENIB; TAXANE DERIVATIVE; THIOTEPA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; DNA DAMAGE; DRUG MEGADOSE; GENE EXPRESSION; GENE MUTATION; HIGH RISK PATIENT; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 80755187961     PISSN: 08886008     EISSN: 15581551     Source Type: Journal    
DOI: 10.3233/BD-2010-0304     Document Type: Article

References (128)

1. E.A. Rakha, M.E. El-Sayed, A.R. Green, A.H. Lee, J.F. Robertson and I.O. Ellis, Prognostic markers in triplenegative breast cancer, Cancer 109(1) (1 Jan 2007), 25-32. (Pubitemid 46120191)
2. L.A. Carey, E.C. Dees, L. Sawyer, L. Gatti, D.T. Moore, F. Collichio et al., The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes, Clin Cancer Res 13(8) (15 Apr 2007), 2329-2334. (Pubitemid 46698581)
3. R. Dent, M. Trudeau, K.I. Pritchard, W.M. Hanna, H.K. Kahn, C.A. Sawka et al., Triple-negative breast cancer: clinical features and patterns of recurrence, Clin Cancer Res 13(15 Pt 1) (1 Aug 2007), 4429-4434. (Pubitemid 47219710)
4. L.A. Carey, C.M. Perou, C.A. Livasy, L.G.Dressler, D. Cowan, K. Conway et al., Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, JAMA 295(21) (7 Jun 2006), 2492-2502. (Pubitemid 43854964)
5. R. Dent,W.M. Hanna, M. Trudeau, E. Rawlinson, P. Sun and S.A. Narod, Pattern of metastatic spread in triple-negative breast cancer, Breast Cancer Res Treat 115(2) (May 2009), 423-428.
6. M. Tischkowitz, J.S. Brunet, L.R. Begin, D.G. Huntsman, M.C. Cheang, L.A. Akslen et al., Use of immunohistochemical markers can refine prognosis in triple negative breast cancer, BMC Cancer 7 (2007), 134.
7. L.N. Harris, G. Broadwater, N.U. Lin, A.Miron, S.J. Schnitt, D. Cowan et al., Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342, Breast Cancer Res 8(6) (2006), R66.
8. T. Sorlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A 98(19) ( 11 Sep 2001), 10869-10874. (Pubitemid 32878711)
9. B.G. Haffty, Q. Yang, M. Reiss, T. Kearney, S.A. Higgins, J. Weidhaas et al., Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer, J Clin Oncol 24(36) (20 Dec 2006), 5652-5657. (Pubitemid 46631305)
10. M.C. Cheang, D. Voduc, C. Bajdik, S. Leung, S. McKinney, S.K. Chia et al., Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype, Clin Cancer Res 14(5) (1Mar 2008), 1368-1376. (Pubitemid 351413917)
11. T.O. Nielsen, F.D. Hsu, K. Jensen, M. Cheang, G. Karaca, Z. Hu et al., Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin Cancer Res 10(16) ( 15 Aug 2004), 5367-5374. (Pubitemid 39100473)
12. J.S. Parker, M. Mullins, M.C. Cheang, S. Leung, D. Voduc, T. Vickery et al., Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol 27(8) (10 Mar 2009), 1160-1167.
13. E. Rakha and J.S. Reis-Filho, Basal-like breast carcinoma: from expression profiling to routine practice, Arch Pathol Lab Med 133(6) (Jun 2009), 860-868.
14. F. Bertucci, P. Finetti, N. Cervera, B. Esterni, F. Hermitte, P. Viens et al., How basal are triple-negative breast cancers? Int J Cancer 123(1) (1 Jul 2008), 236-240. (Pubitemid 351705215)
15. E.A. Rakha, S.E. Elsheikh, M.A. Aleskandarany, H.O. Habashi, A.R. Green, D.G. Powe et al., Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes, Clin Cancer Res 15(7) (1 Apr 2009), 2302-2310.
16. D.S. Tan, C. Marchio, R.L. Jones, K. Savage, I.E. Smith, M. Dowsett et al., Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracyclinetreated patients, Breast Cancer Res Treat 111(1) (Sep 2008), 27-44. (Pubitemid 352009225)
17. B.T. Hennessy, A.M. Gonzalez-Angulo, K. Stemke-Hale, M.Z. Gilcrease, S. Krishnamurthy, J.S. Lee et al., Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics, Cancer Res 69(10) (15 May 2009), 4116-4124.
18. T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J.S. Marron, A. Nobel et al., Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci U S A 100(14) (8 Jul 2003), 8418-8423. (Pubitemid 36842560)
19. N.C. Turner and J.S. Reis-Filho, Basal-like breast cancer and the BRCA1 phenotype, Oncogene 25(43) (25 Sep 2006), 5846-5853. (Pubitemid 44453440)
20. M.E. Moynahan, J.W. Chiu, B.H. Koller and B.H. Jasin, Brca1 controls homology-directed DNArepair, Mol Cell 4(4) (Oct 1999), 511-518.
21. N.C. Turner, J.S. Reis-Filho, A.M. Russell, R.J. Springall, K. Ryder, D. Steele et al., BRCA1 dysfunction in sporadic basal-like breast cancer, Oncogene 26(14) (29 Mar 2007), 2126-2132. (Pubitemid 46514749)
22. N. Turner, A. Tutt and A. Ashworth, Targeting the DNA repair defect of BRCA tumours, Curr Opin Pharmacol 5(4) (Aug 2005), 388-393. (Pubitemid 40932041)
23. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature 434(7035) (14 Apr 2005), 917-921. (Pubitemid 40559006)
24. N. Turner, A. Tutt and A. Ashworth, Hallmarks of 'BRCAness' in sporadic cancers, Nat Rev Cancer 4(10) (Oct 2004), 814-819.
25. R. Rouzier, C.M. Perou, W.F. Symmans, N. Ibrahim, M. Cristofanilli, K. Anderson et al., Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin Cancer Res 11(16) ( 15 Aug 2005), 5678-5685. (Pubitemid 41170290)
26. C. Liedtke, C. Mazouni, K.R. Hess, F. Andre, A. Tordai, J.A. Mejia et al., Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol 26(8) (10 Mar 2008), 1275-1281.
27. F. Kassam, K. Enright, R. Dent, G. Dranitsaris, J. Myers, C. Flynn et al., Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design, Clin Breast Cancer 9(1) (Feb 2009), 29-33.
28. L.J. Esserman, Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The ISPY TRIAL (CALGB 150007/150012, ACRIN 6657), Journal of Clinical Oncology (2009), Abstr (515).
29. W.F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer,.Valero et al.,Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy, J Clin Oncol 25(28) (1 Oct 2007), 4414-4422. (Pubitemid 350013847)
30. C. Le Tourneau, 47% pathologic complete response rate to anthracycline-based associated high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients, Breast Cancer Res Treat (2007) Abstr (4010).
31. G. von Minckwitz, Impact of treatment characteristics on response of different breast cancer subtypes: pooled multilayer analysis of the German neoadjuvant chemotherapy trials, J Clin Oncol 28 (2010) Abstr (501).
32. A. Bhattacharyya, U.S. Ear, B.H. Koller, R.R.Weichselbaum and D.K. Bishop, The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin, J Biol Chem 275(31) (4 Aug 2000), 23899-23903. (Pubitemid 30624678)
33. J.E. Quinn, R.D. Kennedy, P.B. Mullan, P.M. Gilmore, M. Carty, P.G. Johnston et al., BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis, Cancer Res 63(19) (1 Oct 2003), 6221-6228. (Pubitemid 37255167)
34. P. Tassone, M.T. Di Martino, M. Ventura, A. Pietragalla, I. Cucinotto, T. Calimeri et al., Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo, Cancer Biol Ther 8(7) (Apr 2009), 648-653.
35. T. Byrski, T. Huzarski, R. Dent, J. Gronwald, D. Zuziak, C. Cybulski et al., Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients, Breast Cancer Res Treat 115(2) (May 2009), 359-363.
36. J. Gronwald, Neoadjuvant therapy with cisplatin in BRCA1- positive breast cancer patients, Journal of Clinical Oncology (2009), Abstr (502).
37. T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka et al., Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy, J Clin Oncol 28(3) (20 Jan), 375-379.
38. J.E. Garber, Neoadjuvant cisplatin (CDDP) in triple negative breast cancer (BC), Breast Cancer Res Treat (2006) (100), S149.
39. D.P. Silver, A.L. Richardson, A.C. Eklund, Z.C. Wang, Z. Szallasi, Q. Li et al., Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer, J Clin Oncol 28(7) (1 Mar), 1145-1153.
40. P.D. Ryan, Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy, Journal of Clinical Oncology (2009) (27) Abstr (551).
41. R. Torrisi, A. Balduzzi, R. Ghisini, A. Rocca, L. Bottiglieri, F. Giovanardi et al., Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel, Cancer Chemother Pharmacol 62(4) (Sep 2008), 667-672.
42. G. Frasci, P. Comella, M. Rinaldo, G. Iodice, M. Di Bonito, M. D'Aiuto et al., Preoperative weekly cisplatin-epirubicinpaclitaxel with G-CSF support in triple-negative large operable breast cancer, Ann Oncol 20(7) (Jul 2009), 1185-1192.
43. W.M. Sikov, D.S. Dizon, R. Strenger, R.D. Legare, K.P. Theall, T.A. Graves et al., Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin andweekly paclitaxelwith orwithout trastuzumab: aBrownUniversity Oncology Group Study, J Clin Oncol 27(28) (1 Oct 2009), 4693-4700.
44. J.P. Leone, Neoadjuvant platinum-based chemotherapy (CT) for triple-neagtive locally advanced breast cancer (LABC): retrospective analysis of 125 patietns, Journal of Clinical Oncology (27) (2009), Abstr (625).
45. B. Sirohi, M. Arnedos, S. Popat, S. Ashley, A. Nerurkar, G. Walsh et al., Platinum-based chemotherapy in triple-negative breast cancer, Ann Oncol 19(11) (Nov 2008), 1847-1852.
46. R. Conforti, T. Boulet, G. Tomasic, E. Taranchon, R. Arriagada, M. Spielmann et al., Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials, Ann Oncol 18(9) (Sep 2007), 1477-1483. (Pubitemid 47365479)
47. M. Cheang, Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF, Journal of Clinical Oncology (2009) Abstr (519).
48. M. De Laurentiis, G. Cancello, D. D'Agostino, M. Giuliano, A. Giordano, E. Montagna et al., Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a metaanalysis of randomized trials, J Clin Oncol 26(1) (1 Jan 2008), 44-53.
49. I.C. Henderson, D.A. Berry, G.D. Demetri, C.T. Cirrincione, L.J. Goldstein, S. Martino et al., Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer, J Clin Oncol 21(6) (15 Mar 2003), 976-983. (Pubitemid 46594124)
50. E.P. Mamounas, J. Bryant, B. Lembersky, L. Fehrenbacher, S.M. Sedlacek, B. Fisher et al., Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for nodepositive breast cancer: results from NSABP B-28, J Clin Oncol 23(16) (1 Jun 2005), 3686-3696.
51. D.F. Hayes, A.D. Thor, L.G. Dressler, D. Weaver, S. Edgerton, D. Cowan et al., HER2 and response to paclitaxel in node-positive breast cancer, N Engl J Med 357(15) (11 Oct 2007), 1496-1506. (Pubitemid 47572635)
52. M. Martin, T. Pienkowski, J. Mackey, M. Pawlicki, J.P. Guastalla, C. Weaver et al., Adjuvant docetaxel for nodepositive breast cancer, N Engl J Med 352(22) (2 Jun 2005), 2302-2313. (Pubitemid 40740554)
53. J. Hugh, J. Hanson, M.C. Cheang, T.O. Nielsen, C.M. Perou, C. Dumontet et al., Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial, J Clin Oncol 27(8) (10 Mar 2009), 1168-1176.
54. M. Martin, A. Rodriguez-Lescure, A. Ruiz, E. Alba, L. Calvo, M. Ruiz-Borrego et al., Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer, J Natl Cancer Inst 100(11) (4 Jun 2008), 805-814. (Pubitemid 351809668)
55. M. Rodriguez-Lescure, Subgroup analysis of GEICAM 9906 trial comparing six cycles of FE90C (FEC) to four cycles of FE90C followed by 8 weekly paclitaxel administrations (FECP):Relevance ofHER2 and hormonal status (HR), Journal of Clinical Oncology (2007), Abstr (10598).
56. D. Loesch, F.A. Greco, N.N. Senzer, H.A. Burris, J.D. Hainsworth, S. Jones et al., Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer, J Clin Oncol 28(18) (20 Jun), 2958-2965.
57. J.A. Sparano, M. Wang, S. Martino, V. Jones, E.A. Perez, T. Saphner et al.,Weekly paclitaxel in the adjuvant treatment of breast cancer, N Engl J Med 358(16) (17 Apr 2008), 1663-1671. (Pubitemid 351549913)
58. H. Joensuu, P.L. Kellokumpu-Lehtinen, R. Huovinen, A. Jukkola-Vuorinen, M. Tanner, R. Asola et al., Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial, LancetOncol 10(12) (Dec 2009), 1145-1151.
59. H. Joensuu. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophophamide (CEF): Efficacy in patients with triple-negative breast cancer, J Clin Oncol 28 (2010), Abstr (531).
60. H.K.-L.P.-L. Joensuu, R. Huovinen, A. Jukkola-Vuorinen, M. Tanner, R. Kokko et al., FinXX Final 5-Year Analysis: Results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer, San Anonio Breast Consortium (2010) (Abstr (S4-1)).
61. R. Eiermann, BCIRG 005 main efficacy analysis: a Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC-T) in women with HER2 normal and axillary lymph node positive early breast cancer, San Antonio Breast Cancer Symposium (2008) Abstr (77).
62. O. Gluz, U.A. Nitz, N. Harbeck, E. Ting, R. Kates, A. Herr et al., Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial, Ann Oncol 19(5) (May 2008), 861-870. (Pubitemid 351649186)
63. S. Rodenhuis, M. Bontenbal, Q.G. van Hoesel, W.M. Smit, M.A. Nooij, E.E. Voest et al., Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer, Ann Oncol 17(4) (Apr 2006), 588-596.
64. D. Berry, High-dose chemotherapywith autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials, Breast Cancer Res Treat (106)(Suppl 1) (2007), S5.
65. Y. Nieto and E.J. Shpall, High-dose chemotherapy for highrisk primary and metastatic breast cancer: is another look warranted? Curr Opin Oncol 21(2) (Mar 2009), 150-157.
66. N.U. Lin, E. Claus, J. Sohl, A.R. Razzak, A.Arnaout and E.P. Winer, Sites of distant recurrence and clinical outcomes in patients withmetastatic triple-negative breast cancer: high incidence of central nervous system metastases, Cancer 113(10) (15 Nov 2008), 2638-2645.
67. L.G. Fulford, J.S. Reis-Filho, K. Ryder, C. Jones, C.E.Gillett, A. Hanby et al., Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival, Breast Cancer Res 9(1) (2007), R4.
68. A.A. Luck, A.J. Evans, A.R.Green, E.A.Rakha, C. Paish and I.O. Ellis, The influence of basal phenotype on the metastatic pattern of breast cancer, Clin Oncol (R Coll Radiol) 20(1) (Feb 2008), 40-45.
69. E.A. Rakha, J.S. Reis-Filho and I.O. Ellis, Basal-like breast cancer: a critical review, J Clin Oncol 26(15) (20May 2008), 2568-2581.
70. M. Smid, Y. Wang, Y. Zhang, A.M. Sieuwerts, J. Yu, J.G. Klijn et al., Subtypes of breast cancer show preferential site of relapse, Cancer Res 68(9) (1 May 2008), 3108-3114.
71. J. O'Shaughnessy, D. Miles, S. Vukelja, V. Moiseyenko, J.P. Ayoub, G. Cervantes et al., Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results, J Clin Oncol 20(12) (15 Jun 2002), 2812-3823.
72. K.S.Albain, S.M.Nag, G. Calderillo-Ruiz, J.P. Jordaan, A.C. Llombart, A. Pluzanska et al., Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment, J Clin Oncol 26(24) (20 Aug 2008), 3950-3957.
73. S. Carrick, S. Parker, N. Wilcken, D. Ghersi, M. Marzo and J. Simes, Single agent versus combination chemotherapy for metastatic breast cancer, Cochrane Database Syst Rev (2) (2005), CD003372.
74. S.M. Swain, F.S. Whaley and M.S. Ewer, Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials, Cancer 97(11) (1 Jun 2003), 2869-2879. (Pubitemid 36605157)
75. D.D. Von Hoff, M.W. Layard, P. Basa, H.L. Davis, Jr., A.L. VonHoff, M. Rozencweig et al., Risk factors for doxorubicininduced congestive heart failure, Ann Intern Med 91(5) (Nov 1979), 710-717. (Pubitemid 10218041)
76. M.E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro et al., Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer, Ann Oncol 15(3) (Mar 2004), 440-449. (Pubitemid 38444547)
77. J. Huober, W. Fett, A. Nusch, M. Neise, M. Schmidt, A. Wischnik et al., A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer, BMC Cancer 10(2).
78. M.J. Piccart-Gebhart, T. Burzykowski, M. Buyse, G. Sledge, J. Carmichael, H.J. Luck et al., Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer, J Clin Oncol 26(12) (20 Apr 2008), 1980-1986.
79. W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar et al., Phase III trial of nanoparticle albuminbound paclitaxel compared with polyethylated castor oilbased paclitaxel in women with breast cancer, J Clin Oncol 23(31) (1 Nov 2005), 7794-7803. (Pubitemid 46657376)
80. S.E. Jones, J. Erban, B. Overmoyer, G.T. Budd, L. Hutchins, E. Lower et al., Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer, J Clin Oncol 23(24) (20 Aug 2005), 5542-5551.
81. J.L. Blum, V. Dieras, P.M. Lo Russo, J. Horton, O. Rutman, A. Buzdar et al., Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients, Cancer 92(7) (1 Oct 2001), 1759-1768. (Pubitemid 32952493)
82. M. Blackstein, C.L.Vogel, R.Ambinder, J. Cowan, J. Iglesias andA.Melemed, Gemcitabine as first-line therapy in patients withmetastatic breast cancer: a phase II trial, Oncology 62(1) (2002), 2-8. (Pubitemid 34124219)
83. P. Fumoleau, F.M. Delgado, T. Delozier, A. Monnier, M.A. Gil Delgado, P. Kerbrat et al., Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy, J Clin Oncol 11(7) (Jul 1993), 1245-1252. (Pubitemid 23199126)
84. H.S. Rugo, Ixabepilone plus capecitabine vs. capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies, San Anonio Breast Consortium (2008), Abstr (3057).
85. E.A. Perez, T. Patel and A. Moreno-Aspitia, Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer, Breast Cancer Res Treat 121(2) (Jun), 261-271.
86. A. Roche, Ixabepilone, an epothilone B analog, is effective in ER, PR, HER-2 negative (triple negative) patients (pts): data from neoadjuvant and metastatic (MBC) trials, Annal of Oncology (2006) Abstr (256).
87. V. Roy, B.R. LaPlant, G.G. Gross, C.L. Bane and F.M. Palmieri, Phase II trial of weekly nab (nanoparticle albuminbound)- paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531), Ann Oncol 20(3) (Mar 2009), 449-453.
88. E.S. Thomas, H.L. Gomez, R.K. Li, H.C. Chung, L.E. Fein, V.F. Chan et al., Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment, J Clin Oncol 25(33) (20 Nov 2007), 5210-5217. (Pubitemid 350232252)
89. G. Hortobagyi, Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials, J Clin Oncol (2008), Abstr (186).
90. M.P. Decatris, S. Sundar and K.J. O'Byrne, Platinum-based chemotherapy in metastatic breast cancer: current status, Cancer Treat Rev 30(1) (Feb 2004), 53-81. (Pubitemid 38240088)
91. G.W. Sledge, Jr., P.J., Sr. Loehrer, B.J. Roth and L.H. Einhorn, Cisplatin as first-line therapy for metastatic breast cancer, J Clin Oncol 6(12) (Dec 1988), 1811-1814. (Pubitemid 19089062)
92. K. Kolaric and A. Roth, Phase II clinical trial of cisdichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer, Cancer Chemother Pharmacol 11(2) (1983), 108-112. (Pubitemid 13023531)
93. Z. Mechl and B. Sopkova, CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer, Neoplasma 31(4) (1984), 431-435. (Pubitemid 14046553)
94. M.E. O'Brien, D.C. Talbot and I.E. Smith, Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule, J Clin Oncol 11(11) (Nov 1993), 2112-2117. (Pubitemid 23332246)
95. M. Martin, E. Diaz-Rubio, A. Casado, P. Santabarbara, J.M. Lopez Vega, E. Adrover et al., Carboplatin: an active drug in metastatic breast cancer, J Clin Oncol 10(3) (Mar 1992), 433-437.
96. K. Kolaric and K. Vukas, Carboplatin activity in untreated metastatic breast cancer patients - results of a phase II study, Cancer Chemother Pharmacol 27(5) (1991), 409-412.
97. N. Koshy, D. Quispe, R. Shi, R. Mansour and G.V. Burton, Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients, Breast 19 (11 Mar 2010), 246-248.
98. H.K. Chew, J.H. Doroshow, P. Frankel, K.A. Margolin, G. Somlo, H.J. Lenz et al., Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer, JClin Oncol 27(13) (1 May 2009), 2163-2169.
99. D.A. Yardley, HA.,3rd. Burris, L. Simons, D.R. Spigel, F.A. Greco, J.H. Barton et al., A phase II trial of gemcitabine/ carboplatin with or without trastuzumab in the firstline treatment of patients with metastatic breast cancer, Clin Breast Cancer 8(5) (Oct 2008), 425-431.
100. J.W. Chia, Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy, Journal of Clinical Oncology (2007), Abstr (1086).
101. J. Folkman, What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82(1) (3 Jan 1990), 4-6. (Pubitemid 20020880)
102. B.P. Schneider and K.D. Miller, Angiogenesis of breast cancer, J Clin Oncol 23(8) (10 Mar 2005), 1782-1790. (Pubitemid 46211430)
103. J.A. Foekens, H.A. Peters, N. Grebenchtchikov, M.P. Look, M.E. Meijer-van Gelder, A. Geurts-Moespot et al., High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer, Cancer Res 61(14) (15 Jul 2001), 5407-5414. (Pubitemid 32694919)
104. B.K. Linderholm, H. Hellborg, U. Johansson, G. Elmberger, L. Skoog, J. Lehtio et al., Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer, Ann Oncol 20(10) (Oct 2009), 1639-1646.
105. K. Miller, M.Wang, J.Gralow,M.Dickler,M.Cobleigh, E.A. Perez et al., Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med 357(26) (27 Dec 2007), 2666-2676.
106. J. O'Shaughnessy, Comaprison of subgroup analyses of PFS from three phase II studies of bevacizumab in combination with chemotherapy in patientswithHER-2 negativemetastatic breast cancer, San Anonio Breast Consortium (2009), Abstr (207).
107. D. Miles, Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC); AVADO, J Clin Oncol (2008) Abstr (LBA1011).
108. N.J. Robert, RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2- negative locally recurrent or metastatic breast cancer (MBC), J Clin Oncol (2009) Abstr (1005).
109. A.M. Brufsky, RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER-2 negative metastatic breast cancer, San Anonio Breast Symposium (2009), Abstr (42).
110. H.J. Burstein, A.D. Elias, H.S. Rugo, M.A. Cobleigh, A.C. Wolff, P.D. Eisenberg et al., Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane, J Clin Oncol 26(11) (10 Apr 2008), 1810-1816.
111. J. Bergh, Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC), J Clin Oncol (2010) Abstr (LBA1010).
112. J. Crown, Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus Cin previously treated advanced breast cancer (ABC), JClinOncol (2010), Abstr (LBA1011).
113. J. Baselga, SOLTI-0701: A multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer, San Anonio Breast Consortium (2009) (Abstr 45).
114. W. Gradishar, A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with paclitaxel in patients with locally recurrent of metastatic breast cancer, San Antonio Breast Consortium (2009) (Abstr 44).
115. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, E. Lopez et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature 434(7035) (14 Apr 2005), 913-917. (Pubitemid 40559005)
116. A. Tutt, A. Robson, J.E. Garber et al., Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer, Journal of Clinical Oncology 27 (2009) Abstr (CRA501).
117. J.A. O'Shaughnessy, Efficacy of BSI-201, a poly (ADPribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer: results of a randomized phase II trial, J Clin Oncol 27(18S) (2009) (Abstr 3).
118. B. Corkery, J. Crown, M. Clynes and M. O'Donovan, Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer, Ann Oncol 20(5) (May 2009), 862-867.
119. L.A. Carey, TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer, J Clin Oncol 26 (2008) (Abstr 1009).
120. J.A. O'Shaughnessy, Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients withmetastatic breast cancer, Breat Cancer Res Treat 106 (2007), 308.
121. S. Thome, Translational correlates, including outcome for patients with ER-/PR-/HER2- (triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer, J Clin Oncol 25 (2007) (Abstr 1071).
122. R.S. Finn, J. Dering, C. Ginther, C.A. Wilson, P. Glaspy, N. Tchekmedyian et al., Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple- negative" breast cancer cell lines growing in vitro, Breast Cancer Res Treat 105(3) (Nov 2007), 319-326. (Pubitemid 47596452)
123. R.S. Finn, Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059, San Anonio Breast Consortium (2009) (Abstr 3118).
124. F.C. Bidard, M.C.Matthieu, P. Chollet, I. Raoefils, C. Abrial, J. Domont et al., p53 status and efficacy of primary anthracyclines/ alkylating agent-based regimen according to breast cancer molecular classes, Ann Oncol 19(7) (Jul 2008), 1261-1265. (Pubitemid 351916575)
125. T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka et al., Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy, J Clin Oncol 28(3) (20 Jan 2010), 375-379.
126. J. Baselga, M. Zambetti, A. Llombart-Cussac, G. Manikhas, E. Kubista, G.G. Steger et al., Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer, JClin Oncol 27(4) (1 Feb 2009), 526-534.
127. + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer, Journal of Clinical Oncology (2007) Abstr (517).
128. J.E. Uhm, Y.H. Park, S.Y. Yi, E.Y. Cho, Y.L. Choi, S.J. Lee et al., Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy, Int J Cancer 124(6) (15 Mar 2009), 1457-1462.